We are live on !
Find out more
Abingworth Portfolio holdings
AUM
$304M
Turnover
0%
1-Year Est. Return
95.02%
This Fund
S&P 500
This Quarter Est. Return
+14.83%
1 Year Est. Return
+95.02%
3 Year Est. Return
+186.67%
5 Year Est. Return
+346.26%
10 Year Est. Return
–
AUM
$120M
AUM Growth
+$15.3M
(+15%)
Cap. Flow
+$36.9M
Cap. Flow % of AUM
Cap. Flow %
30.81%
Top 10 Holdings %
Top 10 Hldgs %
93.81%
Holding
21
New
1
Increased
2
Reduced
2
Closed
4
Avg Time Held
1.4
years
Top 10 Avg Time Held
1
year
Top 20 Avg Time Held
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRISPR Therapeutics
CRSP
|
+$48.6M |
| 2 |
Ocugen
OCGN
|
+$1.65M |
| 3 |
ANTH
Anthera Pharmaceuticals, Inc.
ANTH
|
+$757K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CEMP
Cempra, Inc.
CEMP
|
+$9.29M |
| 2 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$2.16M |
| 3 |
Aurinia Pharmaceuticals
AUPH
|
+$1.38M |
| 4 |
Regulus Therapeutics
RGLS
|
+$1.08M |
| 5 |
Achieve Life Sciences
ACHV
|
+$195K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
CRISPR Therapeutics
CRSP
$4.44B
| $52M | 43.5% |
+2,601,814
| New | +$48.6M |
2016 Q4
0 quarters
|
|
|
PRTK
2
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $20M | 16.7% |
1,301,413
| – | – |
2014 Q4
8 quarters
|
|
|
SIEN
3
DELISTED
Sientra, Inc.
SIEN
| $18.7M | 15.62% |
219,901
| – | – |
2014 Q4
8 quarters
|
|
|
NOVN
4
DELISTED
Novan, Inc. Common Stock
NOVN
| $5.38M | 4.49% |
20,000
| – | – |
2016 Q3
1 quarter
|
|
|
CHMA
5
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $3.95M | 3.3% |
2,080,595
| – | – |
2015 Q3
5 quarters
|
|
6
Protara Therapeutics
TARA
$161M
| $3.63M | 3.04% |
50,447
| – | – |
2014 Q4
8 quarters
|
|
7
DELISTED
Cymabay Therapeutics
CBAY
| $2.72M | 2.27% |
1,600,000
| – | – |
2015 Q3
5 quarters
|
|
8
DELISTED
Dermira, Inc.
DERM
| $2.12M | 1.77% |
70,000
| – | – |
2015 Q3
5 quarters
|
|
|
EVAR
9
DELISTED
Lombard Medical, Inc.
EVAR
| $2.03M | 1.7% |
3,473,452
| – | – |
2014 Q3
9 quarters
|
|
10
Cellectis
CLLS
$139M
| $1.69M | 1.41% |
100,000
| – | – |
2015 Q4
4 quarters
|
|
|
11
Ocugen
OCGN
$326M
| $1.44M | 1.2% |
14,815
+11,867
| +403% | +$1.65M |
2016 Q3
1 quarter
|
|
12
Senseonics Holdings Inc
SENS
$551M
| $1.38M | 1.15% |
25,844
| – | – |
2016 Q2
2 quarters
|
|
|
ANTH
13
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
| $1.17M | 0.98% |
107,715
+43,710
| +68% | +$757K |
2013 Q2
14 quarters
|
|
|
IMDZ
14
DELISTED
Immune Design Corp.
IMDZ
| $1.08M | 0.9% |
197,300
| – | – |
2016 Q2
2 quarters
|
|
|
ADAP
15
DELISTED
Adaptimmune Therapeutics
ADAP
| $1M | 0.84% |
250,000
| – | – |
2015 Q4
4 quarters
|
|
|
DRNA
16
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $973K | 0.81% |
337,825
-607,932
| -64% | -$2.16M |
2014 Q1
11 quarters
|
|
|
INNL
17
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
| $360K | 0.3% |
537,235
-18,320
| -3% | -$68K |
2015 Q2
6 quarters
|
|
|
18
Achieve Life Sciences
ACHV
| – | – |
-180
| Closed | -$195K | – |
|
|
19
Aurinia Pharmaceuticals
AUPH
$2.17B
| – | – |
-437,994
| Closed | -$1.38M | – |
|
|
20
DELISTED
Regulus Therapeutics
RGLS
| – | – |
-2,728
| Closed | -$1.08M | – |
|
|
CEMP
21
DELISTED
Cempra, Inc.
CEMP
| – | – |
-383,935
| Closed | -$9.29M | – |
|
Similar funds
LDFR
MPAM
CDIA
GTCM
Abingworth's Q4 2016 Portfolio in Review
As of Q4 2016, Abingworth held 21 positions worth $120M, up 15% from $104M the previous quarter. Its ten largest holdings account for 94% of the portfolio.
Abingworth deployed $36.9M of net new capital in Q4 2016, opening 1 new position and adding to 2 existing holdings. Its largest new stake was CRISPR Therapeutics: 2,601,814 shares worth $52M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Dicerna Pharmaceuticals, Inc., an estimated $2.16M trimmed.
- Abingworth's largest Q4 2016 buy was CRISPR Therapeutics: 2,601,814 shares worth $52M.
- Abingworth added most to Ocugen in Q4 2016, an estimated $1.65M increase.
- Abingworth's biggest Q4 2016 reduction was Dicerna Pharmaceuticals, Inc., cutting an estimated $2.16M.
- Abingworth fully exited Cempra, Inc. in Q4 2016, selling an estimated $9.29M.
- Abingworth's ten largest holdings make up 94% of its $120M portfolio in Q4 2016.
- Abingworth opened 1 new position and closed 4 in Q4 2016.
- Abingworth's portfolio value rose 15% quarter-over-quarter to $120M.
Based on Abingworth's 13F filing for Q4 2016, filed 14 Feb 2017.